AQR Capital Management
PRLD icon

AQR Capital Management’s Prelude Therapeutics PRLD Stock Holding History

AQR Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,500
Closed -$15.1K – 3626
2025
Q3 		$15.1K Sell
10,500
-33,147
-76% -$33.2K ﹤0.01% 3453
2025
Q2 		$35.3K Buy
43,647
+9,824
+29% +$8.51K ﹤0.01% 3256
2025
Q1 		$26K Buy
33,823
+21,330
+171% +$19.9K ﹤0.01% 3117
2024
Q4 		$15.9K Buy
+12,493
New +$16.6K ﹤0.01% 2850

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AQR Capital Management's PRLD Position: Q4 2025 in Review

AQR Capital Management sold out of Prelude Therapeutics (PRLD) in Q4 2025, closing a stake of 10,500 shares — an estimated $15.1K sold.

AQR Capital Management first reported a position in PRLD in Q4 2024 and held it in 4 quarters. The position peaked at $35.3K in Q2 2025. 48 funds tracked by Wall St. Rank hold PRLD as of Q4 2025.

  • AQR Capital Management reported no remaining Prelude Therapeutics position as of Q4 2025 after selling out during the quarter.
  • AQR Capital Management sold 10,500 Prelude Therapeutics shares in Q4 2025, an estimated $15.1K.
  • AQR Capital Management first reported a position in Prelude Therapeutics in Q4 2024 and held it in 4 quarters.
  • AQR Capital Management's Prelude Therapeutics position peaked at $35.3K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2025.

Based on AQR Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.